MiMedx Group, Inc. (NASDAQ:MDXG) Shares Acquired by Paradigm Capital Management Inc. NY

Paradigm Capital Management Inc. NY lifted its holdings in MiMedx Group, Inc. (NASDAQ:MDXG) by 6.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,167,200 shares of the company’s stock after purchasing an additional 258,700 shares during the quarter. MiMedx Group comprises about 1.3% of Paradigm Capital Management Inc. NY’s portfolio, making the stock its 24th biggest position. Paradigm Capital Management Inc. NY owned approximately 2.82% of MiMedx Group worth $28,879,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new stake in MiMedx Group in the first quarter worth about $27,000. Isthmus Partners LLC boosted its stake in MiMedx Group by 30.4% in the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after purchasing an additional 91,714 shares in the last quarter. Quest Partners LLC purchased a new stake in MiMedx Group during the 2nd quarter worth approximately $81,000. Entropy Technologies LP purchased a new stake in MiMedx Group during the 1st quarter worth approximately $99,000. Finally, Shell Asset Management Co. acquired a new position in MiMedx Group during the 1st quarter valued at approximately $113,000. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on MDXG. Craig Hallum dropped their price objective on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price target on shares of MiMedx Group in a research report on Thursday, August 1st. Finally, StockNews.com raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 4th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Price Performance

NASDAQ:MDXG opened at $6.13 on Tuesday. The firm’s fifty day moving average is $6.67 and its two-hundred day moving average is $7.00. The firm has a market cap of $904.81 million, a price-to-earnings ratio of 13.93 and a beta of 1.98. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.22 and a current ratio of 3.85. MiMedx Group, Inc. has a one year low of $5.57 and a one year high of $9.27.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.08. The business had revenue of $87.21 million during the quarter, compared to analysts’ expectations of $88.44 million. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. Research analysts expect that MiMedx Group, Inc. will post 0.26 EPS for the current year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.